Capital International Investors Has $36.02 Million Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Capital International Investors trimmed its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 6.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,017,195 shares of the medical device company’s stock after selling 66,366 shares during the quarter. Capital International Investors owned 1.57% of Tandem Diabetes Care worth $36,019,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Headlands Technologies LLC acquired a new stake in shares of Tandem Diabetes Care in the first quarter worth about $35,000. MCF Advisors LLC lifted its position in shares of Tandem Diabetes Care by 79.3% in the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after buying an additional 445 shares during the last quarter. Signaturefd LLC lifted its position in shares of Tandem Diabetes Care by 871.8% in the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock worth $50,000 after buying an additional 1,517 shares during the last quarter. Arcadia Investment Management Corp MI lifted its position in shares of Tandem Diabetes Care by 141.6% in the first quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock worth $66,000 after buying an additional 1,085 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new stake in shares of Tandem Diabetes Care in the fourth quarter worth about $73,000.

Tandem Diabetes Care Trading Down 1.5 %

NASDAQ:TNDM traded down $0.60 during trading hours on Friday, hitting $40.05. 4,859,266 shares of the stock were exchanged, compared to its average volume of 1,685,761. The company’s 50 day moving average is $45.56 and its two-hundred day moving average is $35.75. Tandem Diabetes Care, Inc. has a twelve month low of $13.82 and a twelve month high of $53.69. The company has a quick ratio of 3.01, a current ratio of 3.81 and a debt-to-equity ratio of 1.43. The company has a market capitalization of $2.59 billion, a P/E ratio of -18.24 and a beta of 1.28.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, May 2nd. The medical device company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.17. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. The firm had revenue of $191.67 million for the quarter, compared to the consensus estimate of $173.06 million. On average, sell-side analysts anticipate that Tandem Diabetes Care, Inc. will post -1.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Dick Allen sold 5,000 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $51.68, for a total value of $258,400.00. Following the transaction, the director now owns 24,396 shares of the company’s stock, valued at approximately $1,260,785.28. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Stifel Nicolaus lifted their price objective on Tandem Diabetes Care from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Oppenheimer boosted their price target on Tandem Diabetes Care from $47.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, June 10th. SVB Leerink upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $34.00 to $45.00 in a research note on Thursday, April 25th. Redburn Atlantic initiated coverage on Tandem Diabetes Care in a research note on Thursday, May 30th. They set a “buy” rating and a $60.00 price target on the stock. Finally, Robert W. Baird boosted their price target on Tandem Diabetes Care from $28.00 to $36.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $51.25.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.